导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.29% | 85/230 |
| 近一周 | -3.12% | 149/244 |
| 近一月 | -8.83% | 194/243 |
| 近一季 | 16.21% | 5/237 |
| 近半年 | 2.89% | 50/233 |
| 近一年 | -14.27% | 153/218 |
| 近两年 | 35.50% | 133/189 |
| 近三年 | -5.78% | 129/159 |
| 成立以来 | -19.58% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.98% 2979/4961 |
-4.25% 3496/5312 |
- - |
- - |
| 2025 | 13.86% 2625/4813 |
4.86% 871/3635 |
4.83% 695/4076 |
17.24% 2539/4524 |
-11.64% 4210/4813 |
| 2024 | -20.67% 2529/3463 |
-16.75% 2566/2808 |
-12.74% 2610/3014 |
20.69% 680/3129 |
-9.52% 2931/3463 |
| 2023 | -12.39% 1474/2656 |
-1.95% 1908/2280 |
-14.12% 2227/2385 |
2.81% 217/2515 |
1.19% 102/2655 |
| 2022 | -23.75% 1164/2207 |
-9.78% 344/1919 |
-2.25% 1769/2016 |
-20.66% 1866/2113 |
8.97% 246/2208 |
| 2021 | -7.28% 1034/1822 |
-0.67% 382/1255 |
16.69% 195/1330 |
-11.95% 1283/1466 |
-9.15% 1594/1822 |
| 2020 | 78.43% 46/1250 |
13.34% 10/1028 |
45.92% 1/1067 |
3.41% 983/1164 |
4.33% 848/1184 |
| 2019 | 52.89% 87/1092 |
34.57% 110/754 |
-1.92% 337/804 |
11.02% 39/850 |
4.35% 807/918 |
| 2018 | -23.52% 284/834 |
- - |
- - |
- - |
-17.15% 647/691 |
| 2017 | 2.56% 440/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.46% 323/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 易方达中证万得生物科技指数(LOF)A VS. 长安沪深300非周期A(740101) |